GlassScriptPhysician profile
G Thomas-Clark
NPI 1043362320
$6,199.63
in general payments reported to CMS, 2019-2025
24 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $422 · 2020: $305 · 2021: $616 · 2022: $1,325 · 2023: $923 · 2024: $2,607.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,530.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,530.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,060.07 | 2020-2024 | Caplyta |
| Tris Pharma INC | $942.72 | 2022-2024 | Dyanavel Xr |
| Supernus Pharmaceuticals, INC. | $685.01 | 2021-2024 | Qelbree |
| Janssen Pharmaceuticals, INC | $533.37 | 2021-2024 | Invega Sustenna |
| Corium, LLC | $498.60 | 2022-2024 | Azstarys |
| Alkermes, INC. | $438.72 | 2019-2024 | Aristada, Lybalvi, Vivitrol |
| Otsuka America Pharmaceutical, INC. | $399.64 | 2021-2024 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Ironshore Pharmaceuticals INC. | $313.97 | 2019-2024 | |
| Teva Pharmaceuticals USA, INC. | $312.02 | 2022-2024 | Austedo Xr, Uzedy, Austedo |
| Sunovion Pharmaceuticals INC. | $253.58 | 2019-2022 | |
| Neurocrine Biosciences, INC. | $170.84 | 2021-2024 | Ingrezza |
| Axsome Therapeutics, INC. | $149.16 | 2023-2024 | Auvelity |
| Lundbeck LLC | $85.07 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $79.97 | 2020-2022 | |
| Indivior INC. | $60.57 | 2020-2024 | Perseris |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sage Therapeutics, LLC | $53.22 | 2024 | |
| Almatica Pharma LLC | $37.33 | 2022 | |
| Tempus Ai, INC | $21.90 | 2024 | |
| Vanda Pharmaceuticals INC. | $19.78 | 2020 | |
| Neos Therapeutics, LP | $19.26 | 2020 | |
| Idorsia Pharmaceuticals US INC | $18.67 | 2023 | Quviviq |
| Acadia Pharmaceuticals INC | $17.11 | 2022 | |
| Abbvie INC. | $14.95 | 2023 | Vraylar |
| Alfasigma USA, INC. | $14.10 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw G Thomas-Clark listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.